BAR-trial: Bioavailability of Ethanol Following Bariatric Surgery
- Conditions
- Obesity, Morbid
- Interventions
- Procedure: Gastric bypassProcedure: gastric sleeve
- Registration Number
- NCT01840020
- Lead Sponsor
- Norwegian University of Science and Technology
- Brief Summary
The first-pass metabolism (FPM) is a barrier to the toxicity of ethanol. Changes to the size and function of the stomach may alter FPM. Bariatric surgery, like the gastric bypass procedure, involves significant changes to the size and function of the stomach and leads to more rapid gastric emptying. Consequences will be faster absorption and higher peak concentration of ethanol after surgery than before. There are growing concerns that surgery for obesity in this way may cause alcohol abuse.
In this study the investigators compare changes in FPM of ethanol following two different bariatric surgical procedures.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
- volunteers from Central Norway
- morbid obese BMI > 40 kg/m2)
- morbid obese BMI > 35 kg/m2 given a obesity related disease that qualifies for bariatric surgery
- previous or current alcohol abuse
- risk for alcohol harm as assessed by AUDIT
- alcohol abstinence
- liver disease except fatty liver, which occurs in more than 50% of those who seek bariatric surgery
- previous colon resection
- not/insufficiently able to informed consent
- drugs that interact with alcohol dehydrogenase
- drugs that slow down emptying of the stomach
- pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Gastric bypass Gastric bypass patients recruited from Central Norway Gastric sleeve gastric sleeve patients recruited from Central Norway
- Primary Outcome Measures
Name Time Method Change in bioavailability of ethanol from baseline to 3 months, 1 year, and 3 years bioavailability tests: Plasma concentration of ethanol. Calculation:
* Area under curve (AUC)
* Maximum concentration(Cmax)
* Time up to maximum concentration (tmax)
* Oral bioavailability (AUCpo/AUCiv)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Sykehuset Namsos
🇳🇴Namsos, Norway
Obesity policlinic of St. Olavs Hospital
🇳🇴Trondheim, Norway